Cargando…

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3

The HER/ErbB family of receptor tyrosine kinases drives critical responses in normal physiology and cancer, and the expression levels of the various HER receptors are critical determinants of clinical outcomes. HER activation is driven by the formation of various dimer complexes between members of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shankaran, Harish, Zhang, Yi, Tan, Yunbing, Resat, Haluk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749947/ https://www.ncbi.nlm.nih.gov/pubmed/23990774 http://dx.doi.org/10.1371/journal.pcbi.1003201

Ejemplares similares

HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells
por: Zhang, Yi, et al.
Publicado: (2009)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas
por: Tang, Daoqiang, et al.
Publicado: (2014)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer
por: Yu, Xiaolin, et al.
Publicado: (2017)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
por: Takagi, Shinji, et al.
Publicado: (2014)

Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix
por: Ueda, Asako, et al.
Publicado: (2017)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

Structure and dynamics of the EGFR/HER2 heterodimer
por: Bai, Xue, et al.
Publicado: (2023)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Axonal Neuregulin Signals Cells of the Oligodendrocyte Lineage through Activation of HER4 and Schwann Cells through HER2 and HER3
por: Vartanian, Timothy, et al.
Publicado: (1997)

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
por: Zhang, Shu, et al.
Publicado: (2016)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
por: Cao, Guo-dong, et al.
Publicado: (2017)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
por: Negrón-Vega, Lisandra, et al.
Publicado: (2022)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b8ds1qvuumnqtj8g900njtq1f2